Which are 5 NZX healthcare stocks to look at ahead of 2022?

Highlights

• NZ has obtained 60K courses of Pfizer’s antiviral drug to help people with minor symptoms from becoming very ill.
• Fisher and Paykel plans to invest in more land and buildings in the next 5 years.
• Arvida Group delivered an underlying profit of $26.6 million in H1FY22, up 30% on pcp. 

NZ’s Health Minister Andrew Little announced on Monday that NZ had procured supplies of another medicine to deal with COVID-19.

NZ’s drug funding agency Pharmac has obtained 60K courses of an antiviral medicine that can be taken as a tablet and help people with minor symptoms from becoming very sick. The drug works by blocking the split of certain proteins essential to produce a fully active virus.

Pfizer’s anti-viral drug is likely to be delivered to NZ in April once it gets MedSafe’s consent.

On this note, let’s skim through how these 5 NZX healthcare stocks are faring as the year ends.

Image source: © 2021 Kalkine Media, Data source- EODHD/Others

Fisher & Paykel Healthcare Corporation Limited (NZX:FPH;ASX:FPH) 

Fisher and Paykel reported a decline of 2% and 1% in its NPAT and operating revenue in H1 of FY22. However, it reported growth in new applications consumables and Homecare operating revenue.

The Group plans to invest in 3 more manufacturing facilities outside NZ over the next 5 years.

FPH ended the day 1.02% in red to close at $31.95.

Ebos Group Limited (NZX:EBO)

Ebos delivered record FY21 results with increased net profit (+15.5%) and increased dividend payments (+14.2%) to shareholders.

RELATED READ: Which are top 5 NZX healthcare stocks in 2021?

Ebos’ key focus areas will be environmental stewardship, packaging waste, responsible supply chain and quality management.

EBO ended the day 0.28% in green to close at $35.46.

Arvida Group Limited (NZX:ARV)

Arvida's underlying profit for the first half of FY22 was $26.6 million, up 30% over the same period last year. High staff expenses, according to the Group, would be a burden for the industry in the second half of FY22.

RELATED ARTICLE: How are NZX retirement villages stocks doing in December 2021?

Arvida has issued an interim dividend of 2.5cps, which will be paid on 15 December.

ARV ended the day 1.02% in red to close at $1.94.

Pacific Edge Limited (NZX:PEB)

Pacific Edge announced a 66% increase in sales to $66.7 million for the six months ending 30 September 2021 on pcp. During that time, the Group's US sales staff grew from 16 to 28 people.

DO READ: Pacific (NZX:PEB): Does the Company have positive growth outlook for 2022?

With scaled-up activities in the United States and a healthy balance sheet, PEB is well positioned to capitalise on commercial opportunities.

PEB ended the day flat to close at $1.25.

Summerset Group Holdings Limited (NZX:SUM; ASX:SNZ)

Summerset announced the auction of occupancy rights for the third quarter of 2021. One hundred ninety-nine transactions were completed throughout the quarter, with 117 new purchases and 82 resales, according to the company.

ALSO READ: Why to look at 4 NZX-listed pharma stocks in 2022?

To date, sales have accounted for 95% of full-year sales in 2020.

SUM ended the day 1.24% in green to close at $13.06.

Bottom Line

Eligible Kiwis have achieved a near-85% vaccination rate. Subsequently, the country is now better prepared to tackle new variants of COVID-19.

(NOTE: Currency is reported in NZ Dollar unless stated otherwise)